Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,036 Cr
verified against source
Revenue YoY
2%
reported change
EBITDA
₹303 Cr
latest reported figure
Source
nse announcements
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene reported Q4 FY26 revenue of ₹1,037 crore (+2% YoY, +13% QoQ) and EBITDA margin of 29%, beating revised guidance. Full-year revenue grew 3% to ~₹4,190 crore, impacted by the Librella destocking headwind. PAT before exceptional items was ₹153 crore (-16% YoY). Management guided for a broadly flat FY27 with EBITDA margins in the mid-20s, as Librella revenue largely disappears in H1. The Bristol-Myers Squibb partnership extension to 2035 and investments in ADC, peptides, and biologics position the company for growth from FY28. Key risk: Librella revenue declines faster than new contracts ramp up, pressuring near-term revenue.
Colored figures show movement against the previous available record.
Guidance to track
- Full-year revenue expected to be broadly flat vs FY26, with H2 meaningfully stronger than H1.
- EBITDA margin guided to mid-20% range through disciplined cost management.
- Librella revenue expected to be near zero in Q1 and Q2, with minor volumes in Q4.
- Preparations progressing; engineering batches expected in FY27 with regulatory approvals to follow.
Risks flagged
- Librella revenue decline will continue to pressure revenue in H1 FY27, with near-zero contribution in Q1 and Q2.
- Bay View costs are only partially capitalized; full impact on P&L not yet known, potentially pressuring margins.
- Section 232 tariffs on pharma products could slow CDMO order flow, though management assesses negligible impact.
- Management cut margin guidance mid-year but beat it; path to high-20s margins remains unclear.
Key quotes
- FY27 will be a transition year for Syngene with important leadership changes already underway to position this company for its next phase of growth, particularly in CDMO, biologics, and emerging AI enabled service lines.
- We expect a broadly flat performance for FY27 while maintaining EBITDA margins in the mid-20s through disciplined cost management and sharper operational executions.
- The Labrella headwinds have clearly had material impacts last year 26 and as we've outlined will continue to have effects through 27 and those are now absorbed in the guidance framework.
Research modules